Zura Bio (NASDAQ:ZURA) Rating Increased to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Zura Bio (NASDAQ:ZURA) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Zura Bio’s Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.20) EPS, FY2024 earnings at ($0.59) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.68) EPS and FY2026 earnings at ($0.62) EPS.

Several other equities analysts also recently weighed in on ZURA. Leerink Partners assumed coverage on Zura Bio in a research report on Monday. They issued an “outperform” rating and a $15.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a report on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating and set a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research report on Monday, October 21st. One analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $16.75.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $4.47 on Monday. Zura Bio has a fifty-two week low of $2.00 and a fifty-two week high of $6.35. The company has a fifty day moving average of $4.17 and a two-hundred day moving average of $4.10.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, sell-side analysts anticipate that Zura Bio will post -0.47 earnings per share for the current year.

Insider Buying and Selling at Zura Bio

In other news, Director Someit Sidhu sold 51,728 shares of Zura Bio stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.10% of the stock is owned by company insiders.

Institutional Trading of Zura Bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new position in Zura Bio in the second quarter valued at approximately $8,446,000. Great Point Partners LLC raised its position in Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after purchasing an additional 1,884,501 shares during the period. Armistice Capital LLC lifted its stake in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares during the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of Zura Bio during the 1st quarter worth $1,157,000. Finally, Palumbo Wealth Management LLC acquired a new stake in shares of Zura Bio during the 3rd quarter worth about $156,000. Institutional investors and hedge funds own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.